Amgen Inc. $AMGN Shares Bought by Bontempo Ohly Capital Mgmt LLC

Key Points

• Bontempo Ohly Capital Mgmt LLC increased its stake in Amgen Inc. by 19.0% during the first quarter, resulting in a total of 9,845 shares valued at approximately $3,067,000.
• Amgen recently announced a quarterly dividend of $2.38 per share, yielding 3.4%, with stockholders of record to be paid on September 12th.
• Amgen's most recent earnings report revealed an EPS of $6.02, surpassing expectations and showing a year-over-year revenue increase of 9.4% to $9.18 billion.

Bontempo Ohly Capital Mgmt LLC raised its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 19.0% during the first quarter, according to its most recent filing with the SEC. The firm owned 9,845 shares of the medical research company's stock after purchasing an additional 1,570 shares during the period. Amgen accounts for about 1.5% of Bontempo Ohly Capital Mgmt LLC's portfolio, making the stock its 24th largest position. Bontempo Ohly Capital Mgmt LLC's holdings in Amgen were worth $3,067,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of AMGN. KPP Advisory Services LLC lifted its holdings in Amgen by 87.1% during the first quarter. KPP Advisory Services LLC now owns 5,833 shares of the medical research company's stock worth $1,817,000 after buying an additional 2,716 shares during the period. Advisor Resource Council bought a new position in shares of Amgen in the 1st quarter worth $1,331,000. Trinity Legacy Partners LLC lifted its stake in shares of Amgen by 3.9% during the 1st quarter. Trinity Legacy Partners LLC now owns 16,132 shares of the medical research company's stock worth $5,026,000 after purchasing an additional 612 shares during the last quarter. DLK Investment Management LLC boosted its position in Amgen by 7.3% during the first quarter. DLK Investment Management LLC now owns 20,491 shares of the medical research company's stock valued at $6,384,000 after purchasing an additional 1,387 shares in the last quarter. Finally, Founders Financial Alliance LLC grew its stake in Amgen by 2.7% in the first quarter. Founders Financial Alliance LLC now owns 1,577 shares of the medical research company's stock valued at $491,000 after purchasing an additional 42 shares during the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

Amgen Stock Performance

Shares of NASDAQ AMGN traded down $6.34 during midday trading on Friday, reaching $276.39. The company had a trading volume of 2,143,109 shares, compared to its average volume of 1,853,902. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $339.17. The business's 50-day simple moving average is $292.54 and its 200 day simple moving average is $291.56. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24. The stock has a market cap of $148.80 billion, a P/E ratio of 22.60, a P/E/G ratio of 2.40 and a beta of 0.49.

Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.28 by $0.74. The firm had revenue of $9.18 billion for the quarter, compared to the consensus estimate of $8.86 billion. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The firm's revenue was up 9.4% on a year-over-year basis. During the same period in the prior year, the firm earned $4.97 EPS. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, September 12th. Investors of record on Friday, August 22nd were issued a dividend of $2.38 per share. The ex-dividend date of this dividend was Friday, August 22nd. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.4%. Amgen's payout ratio is 77.84%.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total transaction of $376,286.33. Following the completion of the sale, the senior vice president directly owned 7,209 shares in the company, valued at approximately $2,141,000.91. The trade was a 14.95% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 0.69% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Wall Street Zen cut shares of Amgen from a "buy" rating to a "hold" rating in a report on Saturday, August 9th. Guggenheim initiated coverage on shares of Amgen in a research note on Tuesday, May 20th. They issued a "neutral" rating and a $288.00 target price for the company. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $305.00 price target on shares of Amgen in a research report on Tuesday, June 24th. Piper Sandler increased their price objective on Amgen from $328.00 to $342.00 and gave the company an "overweight" rating in a report on Monday, August 25th. Finally, Bank of America raised their price objective on Amgen from $252.00 to $261.00 and gave the stock an "underperform" rating in a research report on Wednesday, July 23rd. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have assigned a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Amgen currently has a consensus rating of "Hold" and a consensus price target of $304.43.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.